| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT00182052 | Adenocarcinoma of the Prostate|Prostate Cancer | Drug: Rosiglitazone|Other: Placebo | Massachusetts General Hospital|Dana-Farber Cancer Institute | Phase 3 | 2000-09-01 | 2013-05-22 |
| NCT00785213 | Healthy | Drug: Rosiglitazone 4 mg Tablets|Drug: Rosiglitazone 4 mg Tablets|Drug: Quinine Sulfate 324 mg Capsules | Mutual Pharmaceutical Company, Inc.|Cetero Research, San Antonio | Phase 1 | 2008-09-01 | 2012-07-31 |
| NCT00065065 | Ulcerative Colitis|Inflammatory Bowel Disease | Drug: Rosiglitazone|Drug: Placebo | James Lewis|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|GlaxoSmithKline|University of Pennsylvania | Phase 2 | 2002-09-01 | 2015-12-04 |
| NCT01706211 | Diabetes Mellitus Non Insulin Dependent Oral Agent Therapy | Drug: BRL 49653C|Drug: Placebo | National Taiwan University Hospital | Phase 3 | 1998-10-01 | 2012-10-12 |
| NCT01100619 | Papillary Thyroid Cancer|Follicular Thyroid Cancer|Huerthle Cell Thyroid Cancer|Renal Cell Carcinoma | Drug: rosiglitazone|Drug: XL184 | Exelixis | Phase 1 | 2010-04-01 | 2013-09-17 |
| NCT00486187 | Type 2 Diabetes Mellitus | Drug: rosiglitazone|Drug: metformin or sulfonylurea | Dr. Milan Gupta|GlaxoSmithKline|Canadian Collaborative Research Network | | 2006-04-01 | 2016-01-27 |
| NCT00405015 | Ischemia-Reperfusion Injury|The Metabolic Syndrome | Drug: rosiglitazone | Radboud University|GlaxoSmithKline | Phase 2 | 2007-04-01 | 2010-08-23 |
| NCT00381238 | Alzheimer's Disease | Drug: rosiglitazone | GlaxoSmithKline | Phase 2 | 2006-06-01 | 2016-10-26 |
| NCT00169832 | Diabetes|Coronary Artery Bypass Grafting | Drug: Rosiglitazone or placebo | Laval University|GlaxoSmithKline | Phase 3 | 2003-06-01 | 2008-10-09 |
| NCT00242593 | Mild Cognitive Impairment | Drug: Rosiglitazone | University of Washington|National Institute on Aging (NIA)|GlaxoSmithKline | Phase 2 | 2006-06-01 | 2011-08-04 |
| NCT02694874 | Malaria | Drug: Rosiglitazone|Drug: Placebo | Centro de Investigacao em Saude de Manhica|University Health Network, Toronto|Barcelona Institute for Global Health | | 2016-02-01 | 2016-07-07 |
| NCT00746174 | Insulin Sensitivity | Drug: Rosiglitazone|Drug: Placebo | University of Texas Southwestern Medical Center|GlaxoSmithKline | Phase 4 | 2004-02-01 | 2008-09-02 |
| NCT00207402 | Hepatitis C | Drug: rosiglitazone | Brooke Army Medical Center|InterMune | Phase 4 | 2005-10-01 | 2012-02-13 |
| NCT00231387 | Non-insulin-dependent Diabetes Mellitus | Drug: rosiglitazone | GlaxoSmithKline | Phase 3 | 2002-09-01 | 2017-01-20 |
| NCT01577095 | Type 2 Diabetes Mellitus With Features of Insulin Resistance | Other: EA + Rosiglitazone|Drug: TZD | China Medical University Hospital | Phase 2 | 2006-04-01 | 2012-04-12 |
| NCT00819910 | Hypertriglyceridemia in Type 4 Hyperlipidemia|Non Diabetic Subjects With Normoglycemia | Drug: Rosiglitazone|Drug: Placebo (Rosiglitazone)|Drug: Placebo (Fenofibrate)|Drug: Fenofibrate | Ahmad Slim|GlaxoSmithKline|Brooke Army Medical Center | Phase 4 | 2008-09-01 | 2014-04-08 |
| NCT00367744 | HIV Infections | Drug: Rosiglitazone|Drug: Placebo | National Institute of Allergy and Infectious Diseases (NIAID)|GlaxoSmithKline | Phase 2 | 2006-07-01 | 2016-12-08 |
| NCT00004180 | Sarcoma | Drug: rosiglitazone maleate | Dana-Farber Cancer Institute|National Cancer Institute (NCI) | Phase 2 | 1999-10-01 | 2017-02-09 |
| NCT02526615 | Insulin Sensitivity|Type 2 Diabetes | Drug: Rosiglitazone|Drug: Metformin|Drug: Placebo | Turku University Hospital|SmithKline Beecham | Phase 4 | 2000-10-01 | 2015-08-14 |
| NCT00369174 | Oral Leukoplakia | Drug: rosiglitazone maleate|Other: laboratory biomarker analysis | National Cancer Institute (NCI) | Phase 2 | 2006-06-01 | 2013-02-12 |
